Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group Co., Ltd., commonly referred to as Harbin Pharma, is a leading player in the pharmaceutical industry, headquartered in Harbin, China. Established in 1997, the company has made significant strides in the development and production of a wide range of pharmaceutical products, including traditional Chinese medicine, chemical drugs, and biopharmaceuticals. With a strong presence in both domestic and international markets, Harbin Pharma is renowned for its commitment to innovation and quality. The company’s core offerings include prescription medications, over-the-counter products, and health supplements, distinguished by their efficacy and adherence to stringent safety standards. Recognised for its robust research and development capabilities, Harbin Pharmaceutical Group has achieved notable milestones, positioning itself as a trusted name in healthcare. Its dedication to advancing medical solutions continues to enhance its reputation within the global pharmaceutical landscape.
DitchCarbon Score
How does Harbin Pharmaceutical Group Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Harbin Pharmaceutical Group Co., Ltd.'s score of 45 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Harbin Pharmaceutical Group Co., Ltd.'s reported carbon emissions
In 2023, Harbin Pharmaceutical Group Co., Ltd. reported total carbon emissions of approximately 4,493,880 kg CO2e for Scope 1, 71,231,080 kg CO2e for Scope 2 (market-based), and a significant 3,563,551,150 kg CO2e for Scope 3 emissions. This data reflects a comprehensive approach to emissions reporting, covering all three scopes. The company has set ambitious climate commitments, aiming for an 88% reduction in Scope 1 emissions by 2045, compared to 2022 levels. Additionally, Harbin Pharmaceutical is striving to peak its emissions by 2030, indicating a proactive stance towards climate action. In the near term, they also target a 36% reduction in Scope 1 emissions by 2030 against the 2022 baseline. These commitments align with industry standards for climate action, demonstrating Harbin Pharmaceutical's dedication to reducing its carbon footprint and contributing to global sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 2,217,510 | 0,000,000 | 0,000,000 |
| Scope 2 | 37,994,740 | 00,000,000 | 00,000,000 |
| Scope 3 | 126,213,440 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Harbin Pharmaceutical Group Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
